Related Experiment Video

Updated: Aug 22, 2026

Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS
08:12

Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS

Published on: November 26, 2018

Limitations of compensation by endogenous atrial natriuretic peptide in heart failure

T Tsutamoto1, T Kanamori, A Wada

  • 1First Department of Internal Medicine Shiga University of Medical Science, Otsu, Japan.

Japanese Circulation Journal
|May 1, 1992
PubMed

Insights

In congestive heart failure (CHF), elevated atrial natriuretic peptide (ANP) levels correlate with cyclic guanosine monophosphate (cGMP) in mild cases but not severe ones. High ANP in severe CHF may indicate limited compensatory function.

Area of Science:

  • Cardiology
  • Endocrinology
  • Biochemistry

Background:

  • Congestive heart failure (CHF) involves complex neurohormonal alterations.
  • Atrial natriuretic peptide (ANP) plays a crucial role in cardiovascular homeostasis.
  • Understanding ANP's role in CHF prognosis is vital for patient management.

Purpose of the Study:

  • To investigate the relationship between endogenous atrial natriuretic peptide (ANP) and cyclic guanosine monophosphate (cGMP) levels in patients with congestive heart failure (CHF).
  • To assess the prognostic value of plasma ANP levels in patients with chronic severe CHF.

Main Methods:

  • Correlational analysis of plasma ANP and cGMP levels in patients with varying CHF severity.
  • Measurement of ANP extraction and cGMP production in pulmonary and systemic circulation.
  • Longitudinal follow-up of severe CHF patients to evaluate prognostic markers.

Main Results:

  • A significant positive correlation between plasma ANP and cGMP was observed in mild to moderate CHF.
  • In severe CHF, cGMP levels plateaued despite high ANP, indicating a potential uncoupling.
  • Plasma ANP levels proved to be a sensitive and specific prognostic indicator in severe CHF patients over a 2-year follow-up.

Conclusions:

  • Down-regulation of ANP receptors coupled to guanylate cyclase may occur in severe CHF.
  • High plasma ANP in severe CHF might reflect limitations in endogenous compensatory mechanisms.
  • Plasma ANP levels offer significant prognostic value in severe CHF, potentially exceeding other clinical parameters.

More Related Videos

Isolation of Atrial Myocytes from Adult Mice08:34

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment08:49

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...